282 related articles for article (PubMed ID: 30179131)
1. New Trends in Liposome-based Drug Delivery in Colorectal Cancer.
Krajewska JB; Bartoszek A; Fichna J
Mini Rev Med Chem; 2019; 19(1):3-11. PubMed ID: 30179131
[TBL] [Abstract][Full Text] [Related]
2. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
[TBL] [Abstract][Full Text] [Related]
4. Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.
Krishnaiah YS; Khan MA
Pharm Dev Technol; 2012; 17(5):521-40. PubMed ID: 22681390
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study.
Ahmed F; Kumari S; Kondapi AK
Pharm Res; 2018 Jul; 35(9):178. PubMed ID: 30014319
[TBL] [Abstract][Full Text] [Related]
7. Liposome technologies towards colorectal cancer therapeutics.
Sang R; Stratton B; Engel A; Deng W
Acta Biomater; 2021 Jun; 127():24-40. PubMed ID: 33812076
[TBL] [Abstract][Full Text] [Related]
8. Methods of overcoming treatment resistance in colorectal cancer.
Temraz S; Mukherji D; Alameddine R; Shamseddine A
Crit Rev Oncol Hematol; 2014 Feb; 89(2):217-30. PubMed ID: 24075059
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the use of sPLA
Pourhassan H; Clergeaud G; Hansen AE; Østrem RG; Fliedner FP; Melander F; Nielsen OL; O'Sullivan CK; Kjær A; Andresen TL
J Control Release; 2017 Sep; 261():163-173. PubMed ID: 28662900
[TBL] [Abstract][Full Text] [Related]
10. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Thomas AM; Kapanen AI; Hare JI; Ramsay E; Edwards K; Karlsson G; Bally MB
J Control Release; 2011 Mar; 150(2):212-9. PubMed ID: 21094191
[TBL] [Abstract][Full Text] [Related]
11. Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
Liang B; Shahbaz M; Wang Y; Gao H; Fang R; Niu Z; Liu S; Wang B; Sun Q; Niu W; Liu E; Wang J; Niu J
Clin Cancer Res; 2015 Mar; 21(5):1183-95. PubMed ID: 25549721
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer.
Zhang J; Wang X; Liu T; Liu S; Jing X
Drug Deliv; 2016; 23(3):794-800. PubMed ID: 24870201
[TBL] [Abstract][Full Text] [Related]
13. Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against
Su M; Wen X; Yu Y; Li N; Li X; Qu X; Elsabahy M; Gao H
J Mater Chem B; 2024 Apr; 12(16):3947-3958. PubMed ID: 38586917
[TBL] [Abstract][Full Text] [Related]
14. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
15. In vitro determination of the efficacy of scorpion venoms as anti-cancer agents against colorectal cancer cells: a nano-liposomal delivery approach.
Al-Asmari AK; Ullah Z; Al Balowi A; Islam M
Int J Nanomedicine; 2017; 12():559-574. PubMed ID: 28144138
[TBL] [Abstract][Full Text] [Related]
16. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
17. Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivo.
Doi Y; Shimizu T; Ishima Y; Ishida T
Int J Pharm; 2019 Jun; 564():237-243. PubMed ID: 31002935
[TBL] [Abstract][Full Text] [Related]
18. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil.
Moghimipour E; Rezaei M; Ramezani Z; Kouchak M; Amini M; Angali KA; Dorkoosh FA; Handali S
Eur J Pharm Sci; 2018 Mar; 114():166-174. PubMed ID: 29247686
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
[TBL] [Abstract][Full Text] [Related]
20. Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.
Rudokas M; Najlah M; Alhnan MA; Elhissi A
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):60-72. PubMed ID: 26938856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
